Home  >  Products  >  MYCNOS (MYCN opposite strand/antisense RNA (non-protein coding) ) Blocking Peptide (the N terminal of MYCNOS)(100ug)
MYCNOS (MYCN opposite strand/antisense RNA (non-protein coding) ) Blocking Peptide (the N terminal of MYCNOS)(100ug)

MYCNOS (MYCN opposite strand/antisense RNA (non-protein coding) ) Blocking Peptide (the N terminal of MYCNOS)(100ug)


Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-MYCNOS Antibody (ARP51638_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP51638
Size: 100ug
Weight: 12kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: The N-myc oncogene has been implicated in the pathogenesis of a number of human tumors, including childhood neuroblastoma and adult small cell lung cancer. Complementary DNA clones derived from a transcription unit, N-cym, located on the opposite DNA strand to N-myc have been characterized. There is extensive overlap between the 5' ends of the two transcription units. The N-cym gene, which can encode a 109-amino acid protein, is expressed during fetal development, as well as in tumor cell lines containing amplified N-myc loci, where it is expressed at very high levels. Although other examples of overlapping, opposite-strand eukaryotic genes exist, N-myc and N-cym are unique in that they appear to be coregulated in tumor cell lines under basal growth conditions and in response to the differentiating agent retinoic acid. This coregulation suggests that their protein products may be functionally interrelated during normal development and oncogenesis.
Alternative names: NCYM; NYCM